To investigate the use of maintenance PARP inhibitors outside the BRCA mutant cohort, the NOVA study [103] recruited eligible patients with recurrent ovarian cancer regardless of BRCA and HRD status; 553 patients were randomised to receive either niraparib or placebo. This evidence concerns the gene PARP1 and ovarian carcinoma.